Cardiology Respiratory Haematology Moderate — validated in prospective cohort studies
DASH Prediction Score for Recurrent VTE
Predicts the annual risk of recurrent VTE after discontinuing anticoagulation following a first unprovoked VTE event, to guide duration of therapy
References
- Tosetto A, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019–1025.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Atracurium Besilate · Non-depolarising Neuromuscular Blocking Agent (Intermediate Duration)
- Bivalirudin (PCI Anticoagulation) · Direct Thrombin Inhibitor / PCI
- Bivalirudin · Anticoagulation
- Naseptin Nasal Cream · Nasal Decolonisation / Recurrent Epistaxis
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.